Skip to main content
OpenTrials
Completed

NCT Number: NCT01421121

Safety and Immunogenicity of an Inactivated EV71 Vaccine in Infants

A randomized, placebo-controlled, double-blind clinical trial is to evaluate the safety and immunogenicity of a new inactivated EV71 vaccine developed by Sinovac Biotech CO., LTD.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 month–35 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

GuangXi Center for Diseases Control and Prevention

Nanning, Guangxi, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy males and females, aged from 6 months to 11 years old Health is determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator
  • Provided legal identification for the sake of recruitment.
  • Subjects and/or parent(s)/legal guardian(s) are able to understand and sign informed consents.
  • Birth weight more than 2500 grams

Exclusion criteria

  • History of Hand-foot-mouth Disease
  • Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine
  • Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
  • Congenital malformations or developmental disorders, genetic defects, or severe malnutrition
  • Epilepsy, seizures or convulsions history, or family history of mental illness
  • Autoimmune disease or immunodeficiency, or parents, brothers and sisters have autoimmune diseases or immunodeficiency
  • History of asthma, angioedema, diabetes or malignancy
  • History of thyroidectomy or thyroid disease that required medication within the past 12 months
  • Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
  • Asplenia, functional asplenia or any condition resulting in the absence or removal the spleen
  • Acute illness or acute exacerbation of chronic disease within the past 7 days
  • Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
  • History of any blood products within 3 months
  • Administration of any live attenuated vaccine within 28 days
  • Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or allergy treatment within 14 days
  • Axillary temperature > 37.0 centigrade before vaccination
  • Abnormal laboratory parameters before vaccination
  • Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent

Treatment and study plan

100U EV71 vaccine with adjuvant

Biological

inactivated vaccine (vero cell) against EV71 of 100U /0.5ml, two doses, 28 days interval

Other names: EV71 vaccine

200 U EV71 vaccine with adjuvant

Biological

inactivated vaccine (vero cell) against EV71 of 200U /0.5ml, two doses, 28 days interval

Other names: EV71 vaccine

400U EV71 vaccine with adjuvant

Biological

inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval

Other names: EV71 vaccine

200U EV71 vaccine without adjuvant

Biological

inactivated vaccine (vero cell) against EV71 without adjuvant of 200U /0.5ml, two doses, 28 days interval

Other names: EV71 vaccine

Placebo

Biological

0.5ml placebo, two doses, 28 days interval

Primary outcomes

  1. Neutralization antibody geometric mean titer in infants 28 days after immunization with EV71 vaccine with or without aluminium hydroxide adjuvant

    Time frame: 6 month

    Primary immunogenicity end point were geometric mean titer of neutralization antibody againt EV71 virus >= 1:8

Secondary outcomes

  1. The rates and severity of solicited adverse events in infants following immunization as a Measure of Safety and Tolerability

    Time frame: 6 months

    solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site.

    solicited general adverse events include Fever, Nausea, Vomiting, Diareahhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy

Sponsors and collaborators

Lead sponsor

Sinovac Biotech Co., Ltd

Industry

Registry information

Important dates

Study start
2011
Primary completion
2011
Study completion
2011
First posted
Aug 22, 2011
Registry last updated
Nov 27, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.